Peptide microarray displaying peptides derived from selected proteins of Epstein-Barr virus (HHV-4).
Number of peptides: 1977 Amount: 1 microarray (1" x 3") Delivery Format: 1-sample peptide microarray Application(s): Antibody epitope discovery, Immune monitoring Indication(s)/Topic(s): Autoimmune disease, Burkitt's lymphoma, Hodgkin's lymphoma, Nasopharyngeal carcinoma Delivery Time: approx. 10 days
PepStar Antigen Collection Microarrays JPT Peptide Technologies applies its unique peptide microarray platform to generate peptide microarrays on glass slides for biomarker discovery, immunomonitoring and detection and validation of protein interactions. Peptides are immobilized on glass slides via a flexible linker by chemoselective coupling. The covalently attached peptides are displayed in three copies on each slide. In addition, multiple identical copies of each microarray are produced. Incubation can be performed manually or automated using only minimal amounts of your sample. Read-out via fluorescence results in low background and high sensitivity.
Benefits of JPT's PepStar™ Microarrays - Screen proteome-wide in a cost, time and sample saving manner - Get hundreds of identical microarray copies - Peptides are free of truncated sequences - Small amounts of your precious samples are needed for incubation - Applicable to a variety of biological samples (e.g. serum, plasma, antibody) - Low background on glass surface - Read-out via fluorescence
Application Notes A Modular Approach for Epitope Discovery and High-Resolution Profiling of Humoral Immune Responses Pawlowski et al. (2013) Full text Multiple Sclerosis and Epstein Barr Virus Infection. An Epitope Mapping Study Reimer et al. (2014) Full text The Challenge of Antigen Sequence Diversity:Solutions with ULTRA Peptide Libraries Pawlowski et al. (2015) Full text Rapid Mimotope Optimization for Pharmacokinetic Analysis of the Novel Therapeutic antibody IMAB362 Daneschar et al. (2014) Full text
Testimonials for JPT's Peptide Microarrays "Over the past five years my research team has been active in the development of species-specific peptide arrays. Our ability to advance this technology into new research areas has been dependent on working with the highest quality of arrays. In this regard, JPT's commitment to excellence has been a critical foundation for the success of our research program. I have been consistently impressed with their customer service, technical expertise and professionalism. When it comes to peptide work there are no other options for our group, JPT is the best." Scott Napper, PhD, Vaccine and Infectious Disease Organization (VIDO), University of Saskatchewan, Canada
"The RV 144 HIV trial is considered as one of first successful HIV vaccine trials. It has become clear that the V2 loop of gp120 is an important site for immunogenicity and protection from HIV infection. The use of JPT's PepStar microarray technology has been very useful for the correlation of the clincial outcome with humoral immune responses. As have the cyclic peptides been from JPT to validate these findings!." Jeff Currier, PhD, Walter Reed Army Institute, Rockville, Maryland, USA
"We study modulation of dopaminergic neurotransmisson by TAAR1 and D2R. The functional interaction of the two receptors in the brain supports TAAR1 as a target for the treatment of psychiatric disorders such as schizophrenia or bipolar disorder. To map the epitopes of our newly generated specific anti-rat TAAR1 antibodies we used JPT's PepStarTM peptide microarrays. The peptide microarrays greatly contributed to our successful and recently published study. We were very satisified with the exceptional product and service delivered by JPT Peptide Technologies as well as their scientific Customer Support which was always at our disposal." Stefan Obermüller, F.Hoffmann - La Roche Ltd., Roche Pharma Research and Early Development, Basel, Switzerland